OncoImmune raises $15M for PhII GvHD study; FDA wraps biosimilar naming guidance
• Rockville, MD-based OncoImmune has raised a $15 million Series A round. 3E Bioventures Capital led the round, which is primarily focused on a therapy that targets the CD24-Siglec pathway. The biotech believes they can follow this target to a new approach in regulating an inflammatory response to tissue injuries, playing a role in autoimmune diseases, cancer and graft-versus-host disease. The lead drug, CD24Fc, is going into Phase II for GvHD.
• The FDA has finalized its guidance on naming non-proprietary biosimilars and biologics.
• Palo Alto, CA-based Palantir has inked a deal to collaborate with Merck KGaA on a program that is designed, in part, to speed up the development of new drugs. Palantir will put its data analytics tech to work on bioinformatics data to help identify patients most likely to benefit from their drugs.
• Israel’s Kitov Pharmaceuticals has acquired tiny TyrNovo, adding immuno-oncology assets. Kitov is paying $2 million in cash and $1.8 million in stock in the deal.